Co not affected by geopolitical tensions in China - CEOLifts full-year EPS forecast
The Anglo-Swedish company said it managed to grow its business in China despite protracted COVID lockdowns and was no longer pursuingAstraZeneca is seen as a bellwether for the pharmaceutical sector in China, which accounted for about 16% of the company's total revenue last year. Despite the headwinds, the company generated 8% sales growth in the region on a constant currency basis in the quarter, whereas it had expected a decline, chief executive Pascal Soriot said on a media call.
Scumbags
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: